AGT's commercial strategy is to develop collaborative research prospects and alliances for product development. This partnership will bring about synergism and "win-win" outcomes addressing complexities in AD health care. At present, AGT does not intend to become a fully integrated global pharmaceutical company, supporting its own independent sales, manufacturing and marketing forces. Rather, AGT's business strategy is to become a discovery and early development evaluation company, focusing on microRNAs as biomarker discovery for diagnosis and therapeutic treatment of Alzheimer's disease and MCI. Our database of microRNAs and their target proteins in circulating plasma, and other knowledge-based discovery of similar key molecules, should provide an attractive position for AGT's collaborative approach to partner with globally oriented pharmaceutical companies in AD health care. AGT's business model is mainly to form alliances with strategic partners of two different types; the first is to perform contract service-oriented R&D for other companies, while pursuing government grant-supported technology development towards AD diagnosis. This will support us to seek the second type of partnership, i.e. dealing with established large pharmaceutical companies capable of developing our tests of expression levels of circulating plasma microRNAs and their target proteins into AD technology products for the marketplace. The AD plasma RNA diagnostic will be the first such deal to be negotiated, thus providing the revenue stream to continue research and development of other pipeline products planned for AGT's Tool Box. The end result will be a valuable and competitive global AD-directed product portfolio, which should continue to be attractive to large AD pharmaceutical companies for strategic alliances.